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ABSTRACT

Oxaliplatin is a third generation anticancer drug that has proven to be successful
in fighting ovarian and testicular cancer. We are interested in determining how
oxaliplatin and oxaliplatin derivatives interact with proteins, as well as how that
interaction is affected by the size and shape of these platinum compounds. We have
synthesized oxaliplatin as it is used in cancer treatment, as well as similar platinum
compounds with the same diaminocyclohexane ligand as oxaliplatin but with additional
bulk added to the nitrogen atoms. We are reacting oxaliplatin with key amino acids,
including methionine, and will be comparing the kinetics of this reaction, as well as the
adducts formed in the reaction, with the bulkier oxaliplatin derivative.

Keywords: oxaliplatin, platinum (II) compounds, anti-cancer drugs, cisplatin, nuclear
magnetic resonance
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CHAPTER 1

INTRODUCTION

With almost 12,000,000 people in the United States having been diagnosed with some
form of cancer, as of 2008, there is really no question as to why cancer treatment has
been a very popular field of research in many scientific disciplines ((1). Cancer
encompasses more than 200 diseases, each with different detection capabilities, growth
rates,, and abilities to spread. It is caused by genetic alterations due to genetics,
environmental factors and lifestyle choices ((2).
). Current methods of treating cancer
include surgery, radiation therapy, and chemotherapy
chemotherapy,, which is treatment using “anti“anti
cancerr drugs.” One of the first and most widely
widely-used anti-cancer
cancer drugs was cisplatin, or
cis-diamminedichloroplatinum(II)
diamminedichloroplatinum(II).

Figure 1. cis-diamminedichloroplatinum(II), or cisplatin.

The cancer-fighting
fighting ability of platinum(II)
platinum(II)-containing
containing compounds was first
discovered by accident in 1965 by the Rosenbe
Rosenberg
rg group at Michigan State University,
when it was observed that the electrolysis of platinum of electrodes generated a platinum
complex that inhibited binary fission in Escherichia coli (E. coli) bacteria. This platinum
complex was found to be cis PtCl2(NH3)2, or cisplatin.
platin. The complex was then tested and
1

proved greatly effective in reducing sarcomas in rats(3). As a result of this serendipitous
finding, cisplatin was developed and approved by the FDA for use in the treatment of
cancer in December 1978 (4). While cisplatin was found to be very successful in treating
testicular and ovarian cancer, there are many disadvantageous side effects associated with
the drug and often led to nausea and vomiting, as well as peripheral neuropathy
experienced by patients In addition, high levels of nephrotoxicity are associated with
cisplatin(5). These high levels of toxicity are thought to be a result of the formation of
adducts between platinum and DNA, as well as adducts between platinum and proteins
(6). In response to these harmful side effects, scientists attempted to synthesize
platinum(II) compounds with the same therapeutic effects of cisplatin but with lower
toxicity. As a result, the second generation anti-cancer drug carboplatin, or cisdiammine(1,1-cyclobutanedicarboxylato)platinum(II) was developed. Carboplatin is
shown to react much more slowly than cisplatin and is known to form complexes with a
longer stability-- two conditions to which its lower nephrotoxicity is attributed (7).
The third generation anti-cancer drug oxaliplatin and an analog of the drug are the
focus of the current research described throughout this paper. Oxaliplatin, or (R,R')-1,2diaminocyclohexaneplatinum(II) oxalate, was approved by the FDA for treatment of
colorectal cancer and cisplatin-resistant tumors (8). The compound consists of a highly
stable diaminocyclohexane (dach) ligand that causes the compound to show a behavior
that highly contrasts that of cisplatin or carboplatin, both of which also have ammine
ligands but different leaving ligands. The reason for this is the inability for the dach
ligand to be released from the platinum atom due to its higher stability caused by chelate
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effect (7); the trans amine ligand in cisplatin and carboplatin can be displaced by the
coordination of a sulfur atom.

Figure 2. (R,R')
(R,R')-1,2-diaminocyclohexaneplatinum(II) oxalate , or oxaliplatin

Platinum(II) compounds are known to form adducts with nucleobases of DNA
and form crosslinks between adjacent nucleobases. These compounds are known to bind
to the N7 of guanine in particular. In addition, platinum(II) ccompounds
ompounds have a high
affinity for sulfur groups, which are often used as "rescue agents" in chemotherapy,
chemotherapy
meaning they reduce binding to certain biomolecules and therefore reduce certain toxic
side effects (7, 9).. The cytotoxicity of these anti
anti-cancer
cancer compounds is thought to be
caused by reactions between the platinum compounds and proteins and peptides, which
leads to the formation of Pt
Pt-DNA
DNA adducts on adjacent guanines. This adduct formation is
shown to activate
ate DNA damage recognition proteins, which eventually leads to
apoptosis, or programmed cell death (8). Since cisplatin reacts more with proteins than
with DNA,, it is essential to study the reactivity of the compounds with sulfur-containing
sulfur
proteins and peptides. Because platinum has a high affinity for sulfur and methionine is
one of two sulfur-containing
containing amino acids, methionine is the main target for platinum
interactions with proteins.

Figure 3. N-Acetyl
Acetyl-Methionine, a derivative
vative of the amino acid methionine
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It is for this reason that a study of the reactivity of both oxaliplatin and the analog
(R,R’)-1,2-dimethyl-diamminocyclohexaneplatinum(II)
diamminocyclohexaneplatinum(II) with the amino acid methionine,
which contains a thioether group and is one of two amino acids containing a sulfur atom.
An area of interest for future work is the reaction between the two compounds and
glutathione, a sulfur-containing
containing peptide.
In a study done by Heudi et al. on the reactions of oxaliplatin and carboplatin with
L-methionine,
methionine, in contrast to cisplatin, it was shown that carboplatin formed the same five
methionine-platinum
platinum adducts, which is sugg
suggestive
estive of carboplatin transforming into
cisplatin in the presence of sodium chloride. Since oxaliplatin contains the dach ligand, a
different amine ligand, this same transformation to cisplatin does not occur (6).
(
It is thought that oxaliplatin's lower toxicity can be attributed to its preferential
reaction with L-methionine
methionine rather than guanosine. In addition, the diaminocyclohexane
ligand of oxaliplatin is highly stable and has the ability to form a wide range of
conformations,
s, including the boat, twist, and chair conformati
conformations
ons due to the presence of
the flexible cyclohexane ring
ring,, with the chair conformation being the most stable and
primary form. After oxaliplatin coordinates to DNA, the diamine
amine ligand remains attached
to thee molecule rather than being released such as in cisplatin and carboplatin.

Figure 4. The structure of (R,R)-N,N’-dimethyl-1,2-diaminocyclohexaneplatinum
inocyclohexaneplatinum oxalate
[Pt(Me2dach)(ox)].
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In our studies, we have used a variety of different techniques to arrive at our
results, including inorganic synthesis, Nuclear Magnetic Resonance (NMR) spectroscopy
for characterization and kinetics studies, and High Performance Liquid Chromatography
(HPLC) for purification of the oxaliplatin analog.
NMR spectroscopy is an essential tool in studying the structure of a molecule. In
the research project described, 1H NMR spectroscopy is used to characterize the
synthesized compounds, as well as monitor the kinetics of experiments with methionine.
1

H NMR spectroscopy gives a separate signal for each hydrogen atom in a compound,

allowing for an accurate assignment of position for each hydrogen atom based on known
chemical shifts characteristic of a certain proton interaction. 1H NMR spectroscopy is
also very useful in studying the kinetics of an experiment, as a spectrum can show you
signals of hydrogens from both the reactants and the products of a reaction. Any signals
displayed in a spectrum that are not characteristic of the reactant are product signals—as
such, you can observe the decrease in the concentration of reactants and subsequent
increase in the concentration of product. The rate of reaction can be monitored by
examining the decrease of the signal of the reactant and the increase of the product signal.
High Performance Liquid Chromatography is a common technique for the
separation and purification of compounds based on polarity. A reverse-phase HPLC
column, as used in the described studies to separate isomers, consists of a non-polar
stationary phase and a polar mobile phase. A non-polar compound will require more
time to elute from the column, whereas a polar compound will elute more quickly. For
cases, such as this, a concentration gradient is used in which both water and a polar

4

solvent are used as the mobile phase, gradually increasing the concentration of the polar
solvent in order to gradually elute the more polar compounds from the column.

5

CHAPTER 2

EXPERIMENTAL METHODS

Synthesis and characterization of Pt(dach)(ox). In order to synthesize
oxaliplatin, a mixture of 64 mg liquid diaminocyclohexane ligand and 5 mL of methanol
were added dropwise to a mixture of 232 mg potassium tetrachloroplatinate and 5 mL
deionized water until a color change to yellow was absorbed and a precipitate was
formed. The reaction yielded 128.8 mg of Pt(dach)Cl2 . 64.8 mg of the Pt(dach)Cl2 was
then reacted with 51.8 mg of silver oxalate to yield 27.9 mg of oxaliplatin, the identity of
which was confirmed by 1H NMR in D2O using a 500 MHz JEOL Eclipse instrument.
Synthesis and characterization of Pt(Me2dach)(ox). Pt(Me2dach)(Cl2) was then
synthesized by adding dropwise 56.8 mg Me2dach in 5.0 mL methanol to 166 mg
potassium tetrachloroplatinate in 5.0 mL deionized water and stirring for a minimum of 2
hours. The product was then converted to Pt(Me2dach)(ox) by reacting 100 mg of
Pt(Me2dach)(Cl2) with 75 mg silver oxalate in 35 mL deionized water. The reaction
stirred overnight and was then filtered and dried. The reaction yielded 72.2 mg of
Pt(Me2dach)(ox), which was confirmed by NMR using the same method as the
Pt(dach)(ox) . NMR and mass spectrometry also confirmed a mixed isomer form of the
product.

6

Figure 5. Reaction mechanism for synthesis of Pt(Me2dach)(ox).

Purification of Pt(Me2dach)(ox). The mixed isomer form of the Pt(Me2dach)(ox)
compound was separated using HPLC. The separation was first tested using an analytical
column and it was found that the isomers could be separated using a gradient of water
and methanol. The separation of the compound was then performed on an apHera C18
Polymer HPLC column (25 cm x 4.6 mm x 5 µm) using a Hitachi Lachrom Elite system.
A concentration gradient of water and methanol was used in 80:20 water:methanol for 120 min., 40:60 for 20-21 min., and 80:20 for 22 minutes and beyond, each at a flow rate
of 0.500 mL/min.
Reaction of Pt(dach)(ox) and N-Ac-Met. The kinetics of the reaction of
Pt(dach)(ox) and N-Ac-Met were monitored in a 2:1 N-Ac-Met:Pt(dach)(ox) ratio in D2O
using a 500 MHz JEOL Eclipse instrument. The reaction was monitored over a 12-hour
period and sporadically throughout the week to ensure no further activity had occurred.
Reaction of Pt(Me2dach)(ox) and N-Ac-Met. The kinetics of the reaction of a
mixed isomer form of Pt(Me2dach)(ox) and N-Ac-Met were monitored in the presence of
excess N-Ac-Met using the same method as the reaction with Pt(dach)(ox). Excess NAc-Met was used due to uncertainty regarding the stoichiometry of the impure isomer. In

7

the near future, reactions of N-Ac-Met and a pure isomer of Pt(Me2dach)(ox) will be
studied.
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CHAPTER 3

RESULTS

The NMR spectra of the Pt(
Pt(dach)(ox) and Pt(Me2dach)(ox) compounds that were
synthesized confirmed the correct identity of the product. The NMR spectrum of
Pt(Me2dach)(ox) is shown
own below in Figure 66.

Figure 6. 1H NMR spectra of Pt(Me2dach)(ox).

lts suggest that the synthesis of Pt(Me2dach)(ox) yielded at least two
NMR results
isomers,, as noted by the two singlet peaks occurring at approximately 2.5 ppm.
ppm The
synthesis of Pt(Me2dach)(o
dach)(ox) is capable of yielding multiple isomers, because the
9

addition of the methyl groups tto the amine nitrogens in the dach ligand creates two chiral
centers, which allows for the possibility of several different stereochemistries. In this
case, the Pt(Me2dach)(ox) can be in (S,R,R,S), (S,R,R,R), or (R,R,R,R) configurations.
configurations
These configurations
ions arise due to the chirality of the compounds and describe the
stereochemistry occurring at the amine nitrogens and the carbons at N, C, C, and N,
respectively. In order to accurately test the kinetics of Me2DachOx, it is necessary that an
isomerically pure form of the compound be obtained. To achieve this, the compound was
separated using HPLC chromatography. Figure 7 shows the HPLC data for the separation
of the Pt(Me2dach)(ox) compound.

Figure 7. HPLC chromatogram of Pt(Me2dach)(ox) .
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As evident in the HPLC spectra, there was a very clear resolution between the two
peaks, which suggest the elution of two isomers with different polarities, with
approximately 7 minutes between the elution of each potential isomer. The isomers were
then collected in separate vials until enough was obtained for experimental use
(approximately 3 mg) and then a small sample was characterized by NMR spectroscopy
to determine which isomer was the most pure and thus the best for reaction with N-AcMet. The NMR spectra of each HPLC peak is shown in Figures 8 and 9 below.
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Figure 8. 1H NMR spectrum of first peak obtained from HPLC separation of Pt(Me2dach)(ox).

Figure 9. 1H NMR spectrum of second peak obtained from HPLC separation of Pt(Me
Pt( 2dach)(ox).

The NMR spectra of the product collected from the major peak, occurring at
approximately
pproximately 7 minutes in the HPLC chromatogram, suggests that the collection from
the first elution is the most pure
pure,, due to the presence of only one singlet signal at
12

approximately 2.5 ppm, and is thought to be of the (S,R,R,S) configuration.
configuration The NMR
spectrum of the second peak eluted at approximately 13 minutes shows two singlet
signals at approximately 2.5 ppm, suggesting a mixed isomer form. It was intended that
this product then be used to study the kinetics of the reaction between Pt(Me2dach)(ox)
and N-Ac-Met,
Met, however mechanical issues with the NMR equipment prevented the
experiment from taking place. Prior to the purification, a kinetics experiment was
performed
med with impure Pt(Me2dach)(ox) and excess N-Ac-Met
Met for preliminary results.
The NMR study of the rea
reaction is shown below in Figure 10.

Figure 10. Column 1 shows the rreaction of oxaliplatin with N-Ac-Met
Met over the span of 10, 100, and 250
minutes, respectively
ctively where a) unreacted S
S-CH3 of N-Ac-Met, b) acetyl-methyl
methyl product, and c) unreacted
N-Ac-Met. Column 2 shows the rreaction of Pt(Me2dach)(ox) with N-Ac-Met
Met over the span of 10, 100, and
250 minutes, respectively where a) unreacted S
S-CH3 of N-Ac-Met, b) acetyl-methyl
methyl product, and c)
unreacted N-Ac-Met.

Though the data obtained from the experiment is not as conclusive as results
yielded from a pure isomer, the data does suggest that no significant change in the
kinetics of the reaction aft
after the addition of bulk (a larger, more sterically hindered
13

group) to the amine nitrogens of oxaliplatin. The NMR spectra above show the reaction
of oxaliplatin with N-Ac-Met and the reaction of Pt(Me2dach)(ox) with N-Ac-Met at 10,
100, and 250 minutes, respectively. The NMR shows that the increase of the acetylmethyl product signal, labeled b. and subsequent decrease of unreacted N-Ac-Met do not
vary greatly between the two reactions. Both reactions completed within approximately
three hours. The NMR spectra does suggest that the reaction of N-Ac-Met with
Pt(Me2dach)(ox) is faster, however this is due to the reaction with Pt(Me2dach)(ox) being
in the presence of excess N-Ac-Met. More conclusive data will be obtained once the
reaction is performed with an isomerically pure form of Pt(Me2dach)(ox).
The NMR spectra above for the kinetics experiment of oxaliplatin and N-Ac-Met
do not show the signal for S-CH3 resonance anticipated in the product. As the amount of
product in the sample increased, the S-CH3 signal should shift due to the coordination of
the sulfur atom to the platinum atom of oxaliplatin. Since this was not observable, we
suspected that our sample had multiple conformations in intermediate exchange, which
broadened the NMR signal. Increasing the temperature of the sample can circumvent the
effect of intermediate exchange, because the rate of exchange increases as temperature
increases. In order to confirm that the product yielded the anticipated S-CH3 peak, a
variable temperature experiment was a 1H NMR spectra of the product was taken at
40°C, 60°C, and 80°C and the results are shown below in Figures 11, 12, and 13,
respectively.
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Figure 11. 1H NMR spectrum of product of kinetics reaction of N
N-Ac-Met
Met and oxaliplatin at 40°C.
40

Figure 12. 1H NMR spectrum of product of kinetics reaction of N
N-Ac-Met
Met and oxaliplatin at 60°C.
60
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Figure 13. 1H NMR spectrum of product of kinetics reaction of N
N-Ac-Met
Met and oxaliplatin at 80°C.
80

The NMR spectra above clearly show that increasing the temperature of the
sample sharpened the signal and revealed the S
S-CH3 partner signal of the sample. The SCH3 signal shifted from approximately 2.1 ppm in the unreacted S
S-CH3 peak as shown in
Figure 10,, peak a. to approximately 2.5 ppm
ppm, was suggests this is the S-CH
CH3 signal of the
product.
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CHAPTER 4

DISCUSSION

Initial results of the kinetics experiences comparing the reactivity of oxaliplatin
and Pt(Me2dach)(ox) with N
N-Ac-Met
Met suggest that the addition of bulk in the form of two
methyls to the amine nitrogen found in oxaliplatin has no significant effect on the kinetics
of the reaction. Both the reaction of oxaliplatin and Pt(Me2dach)(ox) with N-Ac-Met
N
finished in approximately three hours. This is an interesting finding, considering
consi
previous research (10) has shown that the addition of bulk to similar platinum compounds
has had a tremendous affect on the reactivity with sulfur
sulfur-containing
containing ligands. In this
study, the addition of two methyls to the two amine nitrogens in platinum ethylenediame
ethylen
dinitrate resulted in a vast decrease in the rate constant in the reaction with N-Ac-Met
N
and
5’-GMP,
GMP, as well as a significant decrease in the rate constant with Guanosine compared
to the original compound with no bulk added.

Figure 15. Platinum ethylenediamine dinitrate
trate and tetramethylethylenediamine dinitrate.
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Table 1. En/Me4En rate constants for reactions with different sulfur-containing
substrates.
Ratio of
En/Me4En
Rate Constants
N-Ac-Met

16

5’-GMP

13

Guanosine

5.4

This disparity in results between the experiments described above and the results
of the previous experiment are at this time thought to be attributed to either the presence
of a tertiary amine in the platinum ethylenediamine dinitrate as opposed to the secondary
amine in Pt(Me2dach)(ox) or perhaps the difference between the nitrate leaving groups
instead of the oxalate leaving group of oxaliplatin and Pt(Me2dach)(ox). It is known that
the oxalate leaving group is not released as easily as other leaving ligands due to its
higher stability and the chelate effect (7).
It is also interesting to note that in previous studies, experimental results
suggested that the added bulk only coordinated to one methionine, suggesting the
18

formation of a mono product (10). Experimental results shown from our work adding
bulk to oxaliplatin suggest that the bulk coordinates to two methionines, suggesting the
formation of a bis product. A 195Pt NMR experiment was performed using the sample
from the kinetics reaction of Pt(Me2dach)(ox) and methionine to determine whether a
mono or bis product was formed. The 195Pt NMR spectrum displayed a peak between 3600 and -3800 ppm, a known characteristic of the PtN2S2 coordination environment,
suggesting the formation of a bis product. In the future, a second 195Pt experiment with
the reaction of pure Pt(Me2dach)(ox) and N-Ac-Met will be performed to determine if a
bis product is also formed in this case.
Future work includes continuing to purify Pt(Me2dach)(ox) in quantities sufficient
for kinetics studies with N-Ac-Met, as well as other sulfur-containing biological ligands,
as well as using NMR to determine the conformation of the isomerically pure form of
Pt(Me2dach)(ox) and using 195Pt NMR to determine whether a bis or mono product is
formed in the reaction with N-Ac-Met.
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